The present invention relates to a novel method for preparing substituted biphenylamines.

The present invention relates to a novel method for preparing substituted biphenylamines.

It is an object of the present invention to provide an excellent method for producing an excellent therapeutic agent.

The solution of the present invention is as shown in the following scheme:

##STR00001## wherein R.sup.1 represents a C1-C6 alkyl group, R.sup.2 represents a C1-C6 alkyl group, and R.sup.3 represents a C1-C6 alkyl group.

The present invention relates to a novel method for producing 2-(4-N,N-dialkylamino-2-hydroxybenzoyl) benzoates.

The present invention relates to a novel method for producing 2-(4-N,N-dialkylamino-2-hydroxybenzoyl) benzoates.

This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.

The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.